Home › Biliary Tract Cancer › Massachusetts
Biliary Tract Cancer clinical trials in Massachusetts
11 studies for Biliary Tract Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Jun 2, 2026 · NCT07197554Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06239194This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06451497Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT04900818From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.